159 related articles for article (PubMed ID: 9151669)
1. Transmembrane domain sequence requirements for activation of the p185c-neu receptor tyrosine kinase.
Chen LI; Webster MK; Meyer AN; Donoghue DJ
J Cell Biol; 1997 May; 137(3):619-31. PubMed ID: 9151669
[TBL] [Abstract][Full Text] [Related]
2. Dimer interface of transmembrane domains for neu/erbB-2 receptor dimerization and transforming activation: a model revealed by molecular dynamics simulations.
Sajot N; Genest M
J Biomol Struct Dyn; 2001 Aug; 19(1):15-31. PubMed ID: 11565846
[TBL] [Abstract][Full Text] [Related]
3. Rotational coupling of the transmembrane and kinase domains of the Neu receptor tyrosine kinase.
Bell CA; Tynan JA; Hart KC; Meyer AN; Robertson SC; Donoghue DJ
Mol Biol Cell; 2000 Oct; 11(10):3589-99. PubMed ID: 11029057
[TBL] [Abstract][Full Text] [Related]
4. Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia.
Webster MK; Donoghue DJ
EMBO J; 1996 Feb; 15(3):520-7. PubMed ID: 8599935
[TBL] [Abstract][Full Text] [Related]
5. Val(659)-->Glu mutation within the transmembrane domain of ErbB-2: effects measured by (2)H NMR in fluid phospholipid bilayers.
Sharpe S; Barber KR; Grant CW
Biochemistry; 2000 May; 39(21):6572-80. PubMed ID: 10828974
[TBL] [Abstract][Full Text] [Related]
6. Transmembrane interactions in the activation of the Neu receptor tyrosine kinase.
Smith SO; Smith C; Shekar S; Peersen O; Ziliox M; Aimoto S
Biochemistry; 2002 Jul; 41(30):9321-32. PubMed ID: 12135353
[TBL] [Abstract][Full Text] [Related]
7. Transmembrane peptides from tyrosine kinase receptor. Mutation-related behavior in a lipid bilayer investigated by molecular dynamics simulations.
Samna Soumana O; Aller P; Garnier N; Genest M
J Biomol Struct Dyn; 2005 Aug; 23(1):91-100. PubMed ID: 15918680
[TBL] [Abstract][Full Text] [Related]
8. Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II.
Webster MK; D'Avis PY; Robertson SC; Donoghue DJ
Mol Cell Biol; 1996 Aug; 16(8):4081-7. PubMed ID: 8754806
[TBL] [Abstract][Full Text] [Related]
9. Structure prediction of the dimeric neu/ErbB-2 transmembrane domain from multi-nanosecond molecular dynamics simulations.
Sajot N; Genest M
Eur Biophys J; 2000; 28(8):648-62. PubMed ID: 10663532
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of p185neu kinase activity and cellular transformation by co-expression of a truncated neu protein.
Qian X; O'Rourke DM; Zhao H; Greene MI
Oncogene; 1996 Nov; 13(10):2149-57. PubMed ID: 8950982
[TBL] [Abstract][Full Text] [Related]
11. Sequence-related behaviour of transmembrane domains from class I receptor tyrosine kinases.
Jones DH; Barber KR; Grant CW
Biochim Biophys Acta; 1998 May; 1371(2):199-212. PubMed ID: 9630629
[TBL] [Abstract][Full Text] [Related]
12. Constitutive receptor activation by Crouzon syndrome mutations in fibroblast growth factor receptor (FGFR)2 and FGFR2/Neu chimeras.
Galvin BD; Hart KC; Meyer AN; Webster MK; Donoghue DJ
Proc Natl Acad Sci U S A; 1996 Jul; 93(15):7894-9. PubMed ID: 8755573
[TBL] [Abstract][Full Text] [Related]
13. Conformation of the transmembrane domain of the c-erbB-2 oncogene-encoded protein in its monomeric and dimeric states.
Brandt-Rauf PW; Pincus MR; Monaco R
J Protein Chem; 1995 Jan; 14(1):33-40. PubMed ID: 7779261
[TBL] [Abstract][Full Text] [Related]
14. Activation of Neu (ErbB-2) mediated by disulfide bond-induced dimerization reveals a receptor tyrosine kinase dimer interface.
Burke CL; Stern DF
Mol Cell Biol; 1998 Sep; 18(9):5371-9. PubMed ID: 9710621
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic activation of the PDGF beta receptor by the transmembrane domain of p185neu*.
Petti LM; Irusta PM; DiMaio D
Oncogene; 1998 Feb; 16(7):843-51. PubMed ID: 9484775
[TBL] [Abstract][Full Text] [Related]
16. Structural analysis of p185c-neu and epidermal growth factor receptor tyrosine kinases: oligomerization of kinase domains.
Murali R; Brennan PJ; Kieber-Emmons T; Greene MI
Proc Natl Acad Sci U S A; 1996 Jun; 93(13):6252-7. PubMed ID: 8692801
[TBL] [Abstract][Full Text] [Related]
17. Strong hydrogen bonding interactions involving a buried glutamic acid in the transmembrane sequence of the neu/erbB-2 receptor.
Smith SO; Smith CS; Bormann BJ
Nat Struct Biol; 1996 Mar; 3(3):252-8. PubMed ID: 8605627
[TBL] [Abstract][Full Text] [Related]
18. Intermolecular association and trans-phosphorylation of different neu-kinase forms permit SH2-dependent signaling and oncogenic transformation.
Qian X; Dougall WC; Fei Z; Greene MI
Oncogene; 1995 Jan; 10(1):211-9. PubMed ID: 7824275
[TBL] [Abstract][Full Text] [Related]
19. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4.
Hart KC; Robertson SC; Kanemitsu MY; Meyer AN; Tynan JA; Donoghue DJ
Oncogene; 2000 Jul; 19(29):3309-20. PubMed ID: 10918587
[TBL] [Abstract][Full Text] [Related]
20. Transmembrane helix packing of ErbB/Neu receptor in membrane environment: a molecular dynamics study.
Aller P; Garnier N; Genest M
J Biomol Struct Dyn; 2006 Dec; 24(3):209-28. PubMed ID: 17054379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
